Browsing by Author "Ferrés Garrido, Marcela Viviana"
Now showing 1 - 20 of 35
Results Per Page
Sort Options
- ItemA rapid method for infectivity titration of Andes hantavirus using flow cytometry(2013) Barriga, Gonzalo P.; Martínez Valdebenito, Constanza; Galeno, Héctor; Ferrés Garrido, Marcela Viviana; Lozach, Pierre Yves; Tischler, Nicole D.
- ItemA Single-Nucleotide Polymorphism of (V3) Integrin Is Associated with the Andes Virus Infection Susceptibility(2019) Martínez Valdebenito, Constanza; Angulo, Jenniffer; Le Corre Pérez, Monique Nicole; Marco, Claudia; Vial, Cecilia; Miquel P., Juan Francisco; Cerda, Jaime; Mertz, Gregory; Vial, Pablo; López Lastra, Marcelo Andrés; Ferrés Garrido, Marcela Viviana
- ItemAmpliación del rango de distribución de Oligoryzomys longicaudatus (Rodentia, Sigmodontinae) en la Patagonia de Chile y primer registro de Hantavirus en la región(2009) Belmar Lucero, Sebastián Antoni; Godoy Moraga, Paula Roxana.; Ferrés Garrido, Marcela Viviana; Palma Vásquez, Ramón Eduardo
- ItemAndes virus infections in the rodent reservoir and in humans vary across contrasting landscapes in Chile(2010) Torres Pérez, Fernando; Palma Vásquez, Ramón Eduardo; Ferrés Garrido, Marcela Viviana
- ItemCaracterización clínica y epidemiológica de infección asociada a atención en salud por virus influenza en pacientes críticos(2019) Gutiérrez, Valentina; Cerda, Jaime; Le Corre Pérez, Monique Nicole; Medina, Rafael; Ferrés Garrido, Marcela Viviana
- ItemDefining the antibody cross-reactome directed against the influenza virus surface glycoproteins(2017) Nachbagauer, R.; Choi, A.; Hirsh, A.; Margine, I.; Lida, S.; Barrera Vásquez, Aldo Vincent; Ferrés Garrido, Marcela Viviana; Albrecht, R.; García, A.; Medina Silva, Rafael Andrés; Bouvier, N.; Ito, K.; Palese, P.; Krammer, F.
- ItemDetección precoz de infección por citomegalovirus en pacientes sometidos a trasplante alogéneico de precursores hematopoyéticos por reacción de polimerasa en cadena cuantitativa en tiempo real(2014) Ceballos, María Elena; Vizcaya Altamirano, María Cecilia; Pavez, D.; Cerda, Jaime; Martínez Valdebenito, C.; Montecinos, L.; Ferrés Garrido, Marcela Viviana
- ItemEarly versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial(2021) Balcells Marty, Maria Elvira; Rojas Orellana, Luis Esteban; Martínez Valdebenito, Constanza Pamela; Ceballos Valdivielso, María Elena Andrea; Ferrés Garrido, Marcela Viviana; Chang Rathkamp, Mayling Raquel; Vizcaya Altamirano, María Cecilia; Mondaca Contreras, Sebastián Patricio; Huete Garín, Isidro Álvaro; Castro López, Ricardo Adolfo; Sarmiento Maldonado, Mauricio; Villarroel Del Pino, Luis Antonio; Pizarro Ibáñez, Alejandra Valentina; Ross Pérez, Patricio Daniel; Santander Toro, Jaime Andrés; Lara Hernández, Bárbara Alejandra; Ferrada Koch, Marcela Patricia; Vargas Salas, Sergio Sebastián; Beltrán Pávez, Carolina; Soto Rifo, Ricardo; Valiente Echeverria, Fernando Andrés; Caglevic, Christian; Mahave, Mauricio; Selman Bravo, Carolina Antoniett; Gazitúa, Raimundo; Briones, José Luis; Villarroel Espíndola, Franz; Balmaceda Araque, Carlos Felipe; Espinoza Sepúlveda, Manuel Antonio; Pereira Garces, Jaime; Nervi Nattero, Bruno; Le Corre Perez, Monique NicoleBackground: Convalescent plasma (CP), despite limited evidence on its efficacy, is being widely used as a compassionate therapy for hospitalized patients with COVID-19. We aimed to evaluate the efficacy and safety of early CP therapy in COVID-19 progression.", "Methods and findings", "The study was an open-label, single-center randomized clinical trial performed in an academic medical center in Santiago, Chile, from May 10, 2020, to July 18, 2020, with final follow-up until August 17, 2020. The trial included patients hospitalized within the first 7 days of COVID-19 symptom onset, presenting risk factors for illness progression and not on mechanical ventilation. The intervention consisted of immediate CP (early plasma group) versus no CP unless developing prespecified criteria of deterioration (deferred plasma group). Additional standard treatment was allowed in both arms. The primary outcome was a composite of mechanical ventilation, hospitalization for >14 days, or death. The key secondary outcomes included time to respiratory failure, days of mechanical ventilation, hospital length of stay, mortality at 30 days, and SARS-CoV-2 real-time PCR clearance rate. Of 58 randomized patients (mean age, 65.8 years; 50% male), 57 (98.3%) completed the trial. A total of 13 (43.3%) participants from the deferred group received plasma based on clinical aggravation. We failed to find benefit in the primary outcome (32.1% versus 33.3%, odds ratio [OR] 0.95, 95% CI 0.32-2.84, p > 0.999) in the early versus deferred CP group. The in-hospital mortality rate was 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17 p = 0.246), mechanical ventilation 17.9% versus 6.7% (OR 3.04, 95% CI 0.54-17.17, p = 0.246), and prolonged hospitalization 21.4% versus 30.0% (OR 0.64, 95% CI, 0.19-2.10, p = 0.554) in the early versus deferred CP group, respectively. The viral clearance rate on day 3 (26% versus 8%, p = 0.204) and day 7 (38% versus 19%, p = 0.374) did not differ between groups. Two patients experienced serious adverse events within 6 hours after plasma transfusion. The main limitation of this study is the lack of statistical power to detect a smaller but clinically relevant therapeutic effect of CP, as well as not having confirmed neutralizing antibodies in donor before plasma infusion.", "Conclusions", "In the present study, we failed to find evidence of benefit in mortality, length of hospitalization, or mechanical ventilation requirement by immediate addition of CP therapy in the early stages of COVID-19 compared to its use only in case of patient deterioration.
- ItemEcology, Genetic Diversity, and Phylogeographic Structure of Andes Virus in Humans and Rodents in Chile(2009) Medina, Rafael; Palma Vásquez, Ramón Eduardo; Ferrés Garrido, Marcela Viviana
- ItemEstrategias para reducir infecciones, uso de antimicrobianos y sus efectos en una unidad de neonatología(2017) Urzúa Baquedano, María Soledad; Ferrés Garrido, Marcela Viviana; García Cañete, Patricia; Sánchez, Amparo; Luco Illanes, Matías Fernando
- ItemEvaluation of monoclonal antibodies that detect conserved proteins from Respiratory Syncytial Virus, Metapneumovirus and Adenovirus in human samples(2018) González Carreño, Liliana Andrea; Vazquez, Yaneisi; Mora, Jorge E.; Palavecino, Christian E.; Bertrand N., Pablo; Ferrés Garrido, Marcela Viviana; Contreras, Ana María; Beckhaus, Andrea A.; Riedel, Claudia; Bueno Ramírez, Susan
- ItemExactitud y utilidad diagnóstica de la IgM en infecciones por Bartonella henselae(2013) Abarca Villaseca, Katia; Winter, Matías; Marsac, Delphine; Palma, Carlos; Contreras, Ana M.; Ferrés Garrido, Marcela Viviana
- ItemHantavirus cardiopulmonary syndrome successfully treated with high-volume hemofiltration(2016) Bugedo Tarraza, Guillermo; Florez, Jorge; Ferrés Garrido, Marcela Viviana; Roessler Barrón, Eric; Bruhn, Alejandro
- ItemHantavirus: descripción de dos décadas de endemia y su letalidad(2018) Reyes Zaldivar, Felipe Tomás; Ferrés Garrido, Marcela VivianaIntroducción: la infección por hantavirus es una zoonosis endémica en Chile. En dos décadas la letalidad ha descendido a una cifra estable de alrededor de un 30%, pese a importantes esfuerzos por disminuirla. Objetivos: describir los eventos que ocurren antes de la hospitalización y analizar la relación entre estas variables y la letalidad, con el objetivo de identificar momentos de intervención para mejorar la sobrevida de los pacientes. Material y Métodos: se analizaron retrospectivamente todos los casos notificados a través del Boletín Notificación Enfermedades de Declaración Obligatoria (ENO), la Encuesta Epidemiológica de Investigación Ambiental de los casos de Hantavirus del Ministerio de Salud de Chile. Resultados: existieron diferencias significativas en la letalidad por HV determinada por zona geográfica, tipo de trabajo y hospital donde se atendió primariamente el caso. Conclusiones: Hantavirus, por su rápida evolución hacia una condición catastrófica debe tenerse siempre presente en el diagnóstico diferencial y proceder en consecuencia para tener un diagnóstico precoz y acceso a un centro hospitalario con experiencia en manejo de esta patología.
- ItemHantaviruses and cardiopulmonary syndrome in South America(2014) Figueiredo, L.; Souza, W.; Ferrés Garrido, Marcela Viviana; Enria, D.
- ItemHigh-dose intravenous methylprednisolone for hantavirus cardiopulmonary syndrome in Chile : a double-blind, randomized controlled clinical trial(2013) Vial, Pablo A.; Valdivieso, Francisca; Ferrés Garrido, Marcela Viviana; Riquelme, Raúl; Rioseco, M. Luisa; Calvo, Mario; Castillo, Constanza; Díaz, Ricardo; Scholz, Luis; Cuiza, Analia
- ItemHIV-1 tropism : a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients(2013) Ferrés Garrido, Marcela Viviana; Montecinos, Luisa; Tello, Mario; Tordecilla, Rocío; Rodríguez, Consuelo; Pérez, Carlos; Beltrán, Carlos; Guzmán Meléndez, María Antonieta; Afani Saud, Alejandro
- ItemIdentification of biomarkers for disease severity in nasopharyngeal secretions of infants with upper or lower respiratory tract viral infectionsBertrand N., Pablo; Vazquez, Yaneisi; Beckhaus, Andrea A.; González Carreño, Liliana Andrea; Contreras Sepúlveda, Ana María; Ferrés Garrido, Marcela Viviana; Padilla Pérez, Oslando; Riedel, Claudia A.; Kalergis Parra, Alexis Mikes; Bueno, Susan M.Lower respiratory tract infections (LRTIs) produced by viruses are the most frequent cause of morbidity and mortality in children younger than 5 years of age. The immune response triggered by viral infection can induce a strong inflammation in the airways and cytokines could be considered as biomarkers for disease severity as these molecules modulate the inflammatory response that defines the outcome of patients. Aiming to predict the severity of disease during respiratory tract infections, we conducted a 1-year follow-up observational study in infants who presented upper or lower respiratory tract infections caused by seasonal respiratory viruses. At the time of enrollment, nasopharyngeal swabs (NPS) were obtained from infants to measure mRNA expression and protein levels of IL-3, IL-8, IL-33, and thymic stromal lymphopoietin. While all cytokines significantly increased their protein levels in infants with upper and lower respiratory tract infections as compared to control infants, IL-33 and IL-8 showed a significant increase in respiratory syncytial virus (RSV)-infected patients with LRTI as compared to patients with upper respiratory tract infection. We also found higher viral loads of RSV-positive samples with a greater IL-8 response at the beginning of the symptoms. Data obtained in this study suggest that both IL-8 and IL-33 could be used as biomarkers for clinical severity for infants suffering from LRTIs caused by the RSV.
- ItemInfección del sitio quirúrgico en niños sometidos a cirugía cardíaca con cierre esternal diferido. Estudio de casos y controles(2016) Retamal, Javiera; Becker Rencoret, Pedro Antonio; González Foretic, Rodrigo Vicente; Ferrés Garrido, Marcela Viviana; Cerda, Jaime; Riquelme, María I.; Pérez, R.; Clavería Rodríguez, Cristian
- ItemInfecciones asociadas a la atención en salud (IAAS) en pacientes pediátricos post-operados de cardiopatías congénitas(2014) Barriga, J.; Cerda, Jaime; Abarca Villaseca, Katia; Ferrés Garrido, Marcela Viviana; Fajuri, P.; Riquelme, M.; Carrillo, D.; Clavería Rodríguez, Cristian